(d) Identifying a subpopulation of NSCLC patients (with ALK rearrangement) who may benefit from the combination of an ALK inhibitor and PD-1 inhibitor must be stratified according to known risk factors (52) and potential biomarkers (e.g., C-reactive protein levels) (53). Here, CRP is linked to non-small cell lung carcinoma.